Profusion of fibroblast foci in patients with idiopathic pulmonary fibrosis does not predict outcome  by Hanak, Viktor et al.
ARTICLE IN PRESS
Respiratory Medicine (2008) 102, 852–8560954-6111/$ - see fr
doi:10.1016/j.rmed.
$Funding: with g
Corresponding au
E-mail address: mProfusion of fibroblast foci in patients with idiopathic
pulmonary fibrosis does not predict outcome$
Viktor Hanaka, Jay H. Ryua, Erika de Carvalhob, Andrew H. Limpera,
Thomas E. Hartmanc, Paul A. Deckerd, Jeffrey L. Myerse,aDivision of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA
bDepartment of Pathology, University of Sa˜o Paulo Medical School, Sa˜o Paulo, Brazil
cDivision of Diagnostic Radiology, Mayo Clinic, Rochester, MN, USA
dDivision of Biostatistics, Mayo Clinic, Rochester, MN, USA
eDivision of Anatomic Pathology, University of Michigan, 2G332 UH, 1500 E. Medical Center Drive, Ann Arbor,
MI 48109-4095, USA
Received 11 November 2007; accepted 13 January 2008
Available online 7 March 2008KEYWORDS
Pulmonary fibrosis;
Interstitial lung
disease;
Usual interstitial
pneumoniaont matter & 2008
2008.01.012
rant support from
thor. Tel.: +1 734
yerjeff@umich.eSummary
Rationale: The prognostic significance of fibroblast foci in surgical lung biopsies from
patients with idiopathic pulmonary fibrosis (IPF) is unclear.
Objectives: We assessed the relationship between profusion of fibroblast foci and survival
in 43 patients with IPF seen at a tertiary referral medical center from 1996 to 2002.
Methods: Fibroblast foci in surgical lung biopsies were counted using a systematic
morphometric point-counting technique. Patients with either clinical or pathologic
evidence of accelerated disease were excluded from analysis. The association of fibroblast
counts with survival was assessed using proportional hazards regression.
Results: The mean age (7SD) of the study population was 6479 years; 26 (60%) patients
were male. The mean (%7SD) profusion of fibroblastic foci was 0.670.7, expressed as a
percentage of total points counted. Fibroblast foci counts did not differ markedly between
upper, middle, and lower lobes. Median survival from the time of biopsy was 2.4 years;
there were 25 (58%) deaths in the follow up period. There was no significant relationship
between profusion of fibroblast foci and survival in the overall group (p ¼ 0.250).
Conclusions: Higher prevalence of fibroblast foci assessed using a simple point-counting
technique applied to surgical lung biopsies is not associated with survival in patients with
clinically stable IPF.
& 2008 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Fibroblast foci in IPF 853Introduction died within 30 days of biopsy also were excluded.Usual interstitial pneumonia (UIP) is the histologic finding
that defines idiopathic pulmonary fibrosis (IPF) and is
characterized by a combination of temporal and geographic
heterogeneity, septal fibromyxoid tissue (‘‘fibroblast foci’’),
and architectural distortion in the form of honeycomb
change and/or scarring.1 Efforts to link histopathologic
parameters to outcome in patients with IPF have yielded
conflicting results, likely related to differences in technique
and patient selection. King et al.2 found shorter mean
survival in IPF patients who had high semiquantitative scores
for ‘‘granulation and young connective tissue’’, a surrogate
for fibroblast foci. Nicholson et al.3 also applied a
semiquantitative technique to demonstrate a relationship
between the extent of fibroblast foci and mortality. Most
recently Tiitto et al.5 and Enomoto et al.4 used two different
quantitative techniques applied to patients with IPF as well
as patients with underlying connective tissue disease and
observed a relationship between extent of fibroblast foci
and survival. In contrast, Flaherty et al.6 and more recently
Collard et al.7 were unable to demonstrate a relationship
between fibroblast foci and survival in patients with IPF.
Fibroblast foci cannot be reliably assessed in patients
with acute exacerbation of IPF, an observation that may
account for some of the discordance in comparisons of
previously published datasets. Acute exacerbation of IPF,
also termed accelerated IPF, refers to a subset of patients
who experience sudden worsening of their disease accom-
panied by new and otherwise unexplained radiological
abnormalities.8–11 Short-term mortality is extremely high,
83% of the most recently reported patients experiencing
death within 3 months of diagnosis.8,9,11 Surgical lung
biopsies from patients with acute exacerbation most
commonly show a combination of diffuse alveolar damage
(DAD) and UIP.8,9,11–13 The organizing phase of DAD is
characterized by extensive interstitial and air space
proliferation of fibroblasts and myofibroblasts that obscure,
ablate and overlap with the more discrete subepithelial
fibroblast foci typical of UIP. Indeed Ambrosini et al.8
characterized the combination of DAD and UIP seen in their
patients with acute exacerbation as ‘‘numerous fibroblast
foci’’. Given the difficulty in accurately assessing fibroblast
foci and the high short-term mortality in patients with acute
exacerbation of IPF, we elected to focus on the prognostic
value of fibroblast foci in patients with stable disease. We
applied an established morphometric technique to lung
biopsies from patients with clinically stable IPF to further
explore the relationship between profusion of fibroblast foci
and survival in our patient population.
Methods
Patient selection
Patients with a clinical diagnosis of IPF and UIP on a surgical
lung biopsy performed at Mayo Clinic Rochester from
January 1996 through December 2002 were included.
Patients with associated connective tissue disease and
patients with concomitant lung neoplasms were excluded.
Patients with accelerated IPF at the time of biopsy or whoAccelerated IPF was defined by concomitant occurrence of
sudden worsening in dyspnea, decreased arterial oxygen
tension at rest, and new areas of ground glass attenuation or
consolidation on radiologic studies in the absence of an
identifiable cause. Lung biopsies showing extensive organiz-
ing pneumonia or DAD superimposed on UIP were also
considered diagnostic of accelerated IPF and excluded from
further analysis. Clinical information was obtained from
medical records. High-resolution computed tomography
(CT) scans performed within 3 months prior to biopsy were
available for review in 33 patients. CT scans were reviewed
by two of us (TEH, JHR) and scored for pattern, distribution,
and extent of involvement. Pulmonary function tests done
within 3 months prior to biopsy were available for review in
37 patients.Analysis of lung tissue specimens
All available slides from surgical lung biopsies were
reviewed and scored by two of us (JLM, EC) without
knowledge of the clinical information. Fibroblast foci were
counted using a conventional point-counting technique.14–16
A 24mm straight line interrupted counting reticle composed
of 21 lines and 42 points (Merz KR-821) was inserted into a
10 eyepiece (Olympus WS10X/22) and used to examine
five randomly selected fields using a 4 objective (Olympus
UPlanFL 4 /0.13) for a total magnification of 40
(23.75mm2/field) in a multiheaded Olympus BX51 micro-
scope. Fibroblast foci were defined as discrete, subepithe-
lial, interstitial areas in which fibroblasts and myofibroblasts
were arranged in a linear fashion within a pale staining
matrix. Areas of intraluminal fibrosis (i.e. organizing
pneumonia) were not included. Fields for analysis were
randomly selected using a mechanical stage without peering
through the eyepieces. The number of points intersecting
fibroblast foci was expressed as a fraction of the total points
counted for each slide (i.e. 42 points/field 5 fields ¼ 210
total points counted per slide) and a mean value calculated
for each sampled site. An average of 4.373.0 (range 1–15)
slides were examined for each case. An overall mean
combining all sampled sites was used for statistical
comparisons to survival as a primary endpoint. Left lung
was biopsied in 19 patients; in 12 patients at two different
sites and in seven patients at one site. Right lung was
biopsied in 24 patients; in four patients at three different
sites, in 10 patients at two different sites, and in 10 patients
at one site. The 73 biopsy specimens included upper lobes
(29), right middle lobe (16) and lower lobes (28).Statistical analysis
Data are presented using mean7SD for continuous variables
and percentages for categorical variables. The time zero for
the survival analysis was defined as the date of the surgical
lung biopsy. Cumulative survival probabilities were esti-
mated using the Kaplan–Meier method. The log rank test
was used to compare survival of groups of patients.
Proportional hazards regression was used to assess the
relationship between fibroblastic foci and survival. In all
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denote clinical significance.
Results
Lung biopsies from 53 patients were reviewed. Two patients
were excluded because histologic findings suggested diag-
noses other than IPF, including amiodarone toxicity and
chronic hypersensitivity pneumonia in one patient each.
Biopsies from eight additional patients showed a combina-
tion of UIP and DAD consistent with accelerated IPF and
were excluded from further analysis resulting in a study
group of 43 patients who satisfied entry criteria. Mean
patient age was 6479 (mean7SD) years and 26 (60%) were
males. Patient demographics are summarized in Table 1.
Chest computed tomograms prior to the biopsy were
available for review in 33 patients. Traction bronchiectasis
(73%) and irregular linear opacities (67%) were the most
common findings. Radiological evidence of honeycomb
change was seen in only six (18%) of patients.
All cases had histologic findings typical of UIP, including
fibroblast foci. Counted points in randomly selected fields
intersected fibroblast foci in only 35 (81%) cases. The mean
(7SD) profusion of fibroblastic foci was 0.670.7% (median
0.5%, range 0–3.8%), expressed as a percent of total points
counted. Profusion of fibroblast foci was similar regardless
of lobe of origin (Table 2).
Follow-up data were available from 5 days to 6.9 years
(median ¼ 1.6 years). The median survival was 2.4 years
with 25 (58%) deaths being observed. There was no
significant relationship between fibroblast foci profusion
and survival (hazard ratio ¼ 0.83; 95% CI 0.60–1.14;
p ¼ 0.250). Additionally, survival was compared betweenTable 1 Clinical findings in 43 patients with UIP/IPF.
Characteristic
Age, years 6479
Male 26 (60)
FVC, % predicted 60716
FEV1, % predicted 65715
DLCO, % predicted 51715
Smoking
Never 15 (35)
Former 26 (60)
Current 2 (5)
Oxygen use prior to biopsy 9 (21)
Values are expressed as n (%) or mean7SD.
Pulmonary function data was available for 37 patients for FVC
and FEV1 and 36 patients for DLCO.
Table 2 Comparison of profusion of fibroblast foci between up
UIP/IPF.
Fibroblast foci in 43 patients Upper lobes (29)
Mean (7SD) 0.5% (70.5%)
Median (range) 0.5% (0–1.9%)subjects with fibroblast foci profusion above and below the
median (score X0.5% and o0.5%, respectively) and there
was no statistically significant difference in survival
(p ¼ 0.279).Discussion
Profusion of fibroblast foci in surgical lung biopsies showing
UIP did not correlate with survival in our patients with IPF.
Our method differed substantially from that used by
previous investigators. We analyzed randomly selected fields
using an inexpensive and quantitative point-counting tech-
nique that was easily applied to all available slides without
regard to other histologic findings in an effort to avoid
potential selection bias. King et al.2 used a 5-point
semiquantitative scale that included not only fibroblast foci
but also intraluminal connective tissue involving either
alveolar spaces (‘‘organizing pneumonia’’) or small airways
(‘‘bronchiolitis obliterans’’). Both fibroblast foci and orga-
nizing pneumonia contributed to the effect of this histo-
pathologic factor on survival. A more recent report analyzed
a subset of the patients previously reported by King and
colleagues and failed to show a relationship between
survival and either organizing pneumonia or fibroblast foci,
thus highlighting the impact of analytical methods.7
Nicholson et al.,3 using a 7-point (0–6) semiquantitative
scale applied independently by two pathologists to a cohort
of 83 biopsies from 53 patients, showed a statistically
significant relationship between the extent of fibroblast foci
and mortality as well as decline in pulmonary function
measured at 6 and 12 months. Semi-quantitative assess-
ments compared favorably to objective measures expressed
as the number of fibroblast foci per mm.2 Their analysis
differed from our own in that ‘‘areas where activity
appeared to be most marked within each biopsy’’ were
specifically chosen for analysis while normal lung and areas
of honeycomb change (‘‘end-stage lung’’) were excluded. A
year later, Flaherty et al.6 were unable to show a relation-
ship between profusion of fibroblast foci and outcome in
patients with IPF unassociated with collagen vascular
disease. These authors used a 4-point semiquantitative
scale applied by two pathology reviewers, and showed a
strong correlation between their method and those pre-
viously published by King and Nicholson. More recently Tiitto
et al.5 counted fibroblast foci assessed by image analysis
applied to a single slide from patients with IPF and as well as
those with underlying systemic connective tissue disease.5
Methods used to select the single analyzed slide were
unstated and therefore it is unclear what selection biases
may have influenced their results. They observed an average
of 76 fibroblast foci/cm2 (range 2–327) in patients with IPF
compared to 50 in patients with connective tissue disease.per, middle, and lower lobe specimens from 43 patients with
Middle lobe (16) Lower lobes (28)
0.6% (70.8%) 0.7% (70.8%)
0.3% (0–2.2%) 0.5% (0–3.8%)
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fibroblast foci/cm2 had shorter median survivals. Their
conclusions were heavily weighted by inclusion of patients
with connective tissue disease who, when segregated by
extent of fibroblast foci (1–50 versus450 fibroblast foci per
cm2), experienced mean survivals of 217 versus 201 months,
respectively, compared to median survivals of 60 and 44
months in patients with IPF. Statistical analysis was applied
only to the combined group (p ¼ 0.0358). Finally, Enomoto
et al.4 applied a different quantitative imaging technique to
derive a quantitative score for fibroblast foci in 16 patients
with IPF and 15 patients with connective tissue disease.
Areas of honeycomb change were specifically excluded from
their analysis. Profusion of fibroblast foci in IPF patients
averaged 1.6770.90% using their method compared to
0.670.7% using our point-counting technique. In their study
the quantitative fibroblast score was a highly significant
predictor of outcome in combined analysis of patients with
IPF and those with connective tissue disease, a finding
biased by the better survival associated with underlying
connective tissue disease in a manner similar to that seen in
the observations of Tiitto and colleagues. The quantitative
fibroblast foci score persisted as an independent predictor
of survival in IPF patients but was less significant
(p ¼ 0.032). It is unclear the extent to which this difference
might have been influenced by the small size of their study
group.
Differences in methods for selecting microscopic fields for
study combined with the analytical differences summarized
above likely account for many of the differences in reported
studies. Our method was intended to avoid bias by randomly
selecting five low-magnification fields, a technique suffi-
cient to subject most of the tissue on a single microscopic
section to analysis. While our study cannot avoid the
sampling bias inherent in any study using small samples
from considerably larger organs involved by a heterogeneous
disease process, our findings indicate that quantitative
assessment of fibroblast foci in surgical lung biopsies is of
limited prognostic value.
Differences in patient selection may also contribute to
differences between our findings and those previously
reported by others. We excluded patients with systemic
connective tissue diseases and included only those with
clinically stable IPF. We excluded patients with accelerated
IPF reasoning that this might be a confounding variable in
studies using length of survival as a primary endpoint.
Organizing pneumonia or the organizing phase of DAD are
common findings in surgical lung biopsies from patients with
acute exacerbation of IPF.11–13 Both of these pathologic
conditions are characterized by abundant ‘‘young’’ con-
nective tissue that is not easily separated from fibroblast
foci. Indeed, the observation by King et al.2 that the extent
of organizing pneumonia was linked to outcome raises the
possibility that some patients may have had accelerated
IPF.2 Tiitto et al.2 included nine patients described as
experiencing accelerated IPF prior to death. They found no
association between fibroblast foci assessed by their
technique and development of accelerated disease, but no
information is provided regarding the interval between
biopsy and death and no statistical measures are provided.
Interestingly these same authors found no relationship
between a clinical diagnosis of accelerated disease andthe finding of DAD in 11 patients at autopsy, a finding that is
unexplained.
Our study population also differed in that the majority in
whom radiological studies were available for review lacked
classical features of UIP, reflecting our practice of using
surgical lung biopsy primarily in patients with atypical
findings on CT scan. The low prevalence of honeycomb
change in our patients may indicate a bias toward patients
with early stage disease although our low median survivals
make this unlikely. Given the selection bias inherent in any
retrospective, referral-based study group it remains un-
certain the extent to which our observations can be applied
to other patient populations.
In summary, we were unable to demonstrate a relation-
ship between the extent of fibroblastic foci assessed by an
established morphometric technique and disease-associated
mortality. While the effect of the sampling bias cannot be
excluded, our data suggest that detailed quantification of
fibroblast foci on surgical lung biopsies may not be a
consistent predictor of patient survival across all patient
groups.Disclosures
There are no disclosures.References
1. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical
relevance of pathologic classification. Am J Respir Crit Care
Med 1998;157(4 Part 1):1301–15.
2. King Jr TE, Schwarz MI, Brown K, et al. Idiopathic pulmonary
fibrosis: relationship between histopathologic features and
mortality. Am J Respir Crit Care Med 2001;164:1025–32.
3. Nicholson AG, Fulford LG, Colby TV, et al. The relationship
between individual histologic features and disease progression
in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med
2002;166:173–7.
4. Enomoto N, Suda T, Kato M, et al. Quantitative analysis of
fibroblastic foci in usual interstitial pneumonia. Chest
2006;130:22–9.
5. Tiitto L, Bloigu R, Heiskanen U, et al. The relationship between
histopathological features and the course of idiopathic pulmon-
ary fibrosis/usual interstitial pneumonia. Thorax 2006;61:
1091–5.
6. Flaherty KR, Colby TV, Travis WD, et al. Fibroblastic foci in usual
interstitial pneumonia: idiopathic versus collagen vascular
disease. Am J Respir Crit Care Med 2003;167(10):1410–5.
7. Collard HR, Cool CD, Leslie KO, Curran-Everett D, Groshong S,
Brown KK. Organizing pneumonia and lymphoplasmacytic
inflammation predict treatment response in idiopathic pulmon-
ary fibrosis. Histopathology 2007;50:258–65.
8. Ambrosini V, Cancellieri A, Chilosi M, et al. Acute exacerbation
of idiopathic pulmonary fibrosis: report of a series. Eur Respir J
2003;22:821–6.
9. Kim DS, Park JH, Park BK, et al. Acute exacerbation of
idiopathic pulmonary fibrosis: frequency and clinical features.
Eur Respir J 2006;27:143–50.
10. Kondoh Y, Taniguchi H, Kawabata Y, et al. Acute exacerbation in
idiopathic pulmonary fibrosis. Analysis of clinical and pathologic
findings in three cases. Chest 1993;103:1808–12.
11. Parambil JG, Myers JL, Ryu JH. Histopathologic features and
outcome of patients with acute exacerbation of idiopathic
ARTICLE IN PRESS
V. Hanak et al.856pulmonary fibrosis undergoing surgical lung biopsy. Chest
2005;128:3310–5.
12. Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbation of
idiopathic pulmonary fibrosis. Am J Respir Crit Care Med
2007;176:636–43.
13. Hyzy R, Huang S, Myers J, Flaherty K, Martinez F. Acute
exacerbation of idiopathic pulmonary fibrosis. Chest
2007;132:1652–8.
14. Gundersen HJ, Bendtsen TF, Korbo L, et al. Some new, simple
and efficient stereological methods and their use in pathologi-
cal research and diagnosis. APMIS 1988;96:379–94.15. Weibel E. Measuring through the microscope: development and
evolution of stereological methods. J Microsc 1989;155(Part 3):
393–403.
16. Weibel ER C-OL. Morphometric methods. In: Crystal RWJ, Barnes
P, Weibel ER, editors. The lung. Scientific Foundations
Second Ed. Philadelphia: Lippincott-Raven Publishers; 1997.
p. 333–44.
